High-dimensional Analysis of T-cell Profiling Variations Following Belimumab Treatment in Systemic Lupus Erythematosus

Overview

Journal Lupus Sci Med

Specialties Allergy & Immunology
Rheumatology

Date 2023 Oct 6

PMID 37802602

Authors

Shinji Maeda

Hiroya Hashimoto

Tomoyo Maeda

Shin-Ya Tamechika

Shuntaro Isogai

Taio Naniwa

Akio Niimi

Affiliations

Soon will be listed here.

Abstract

Objective: This study sought to elucidate the molecular impacts of belimumab (BEL) treatment on T-cell immune profiling in SLE.

Methods: We used mass cytometry with 25 marker panels for T-cell immune profiling in peripheral blood T cells (CD3+) from 22 patients with BEL-treated SLE and 20 controls with non-BEL-treated SLE. An unsupervised machine-learning clustering, FlowSOM, was used to identify 39 T-cell clusters (TCLs; TCL01-TCL39). TCLs (% of CD3+) showing significant (p<0.05) associations with BEL treatment (BEL-TCL) were selected by a linear mixed-effects model for comparing groups of time-series data. Furthermore, we analysed the association between BEL treatment and variations in regulatory T-cell (Treg) phenotypes, and the ratio of other T-cell subsets to Treg as secondary analysis.

Results: Clinical outcomes: BEL treatment was associated with a decrease in daily prednisolone use (coef=-0.1769, p=0.00074), and an increase in serum CH50 (coef=0.4653, p=0.003), C3 (coef=1.1047, p=0.00001) and C4 (coef=0.2990, p=0.00157) levels. Molecular effects: five distinct BEL-TCLs (TCL 04, 07, 11, 12 and 27) were identified. Among these, BEL-treated patients exhibited increased proportions in the Treg-like cluster TCL11 (coef=0.404, p=0.037) and two naïve TCLs (TCL04 and TCL07). TCL27 showed increased levels (coef=0.222, p=0.037) inversely correlating with baseline C3 levels. Secondary analyses revealed associations between BEL treatment and an increase in Tregs (coef=1.749, p=0.0044), elevated proportions of the fraction of Tregs with inhibitory function (fTregs, coef=0.7294, p=0.0178) and changes in peripheral helper T cells/fTreg (coef=-4.475, p=0.0319) and T helper 17/fTreg ratios (coef=-6.7868, p=0.0327). Additionally, BEL was linked to variations in T-cell immunoglobulin and mucin domain-containing protein-3 expression (coef=0.2422, p=0.039).

Conclusions: The study suggests an association between BEL treatment and variations in T cells, particularly Tregs, in SLE pathologies involving various immune cells.

Citing Articles

Mass cytometry: exploring the immune landscape of systemic autoimmune and inflammatory diseases in the past fourteen years.

Kante A, Chevalier M, Sene D, Chauffier J, Mouly S, Chousterman B Front Immunol. 2025; 15:1509782.

PMID: 39896815 PMC: 11782038. DOI: 10.3389/fimmu.2024.1509782.

Systemic lupus in the era of machine learning medicine.

Zhan K, Buhler K, Chen I, Fritzler M, Choi M Lupus Sci Med. 2024; 11(1).

PMID: 38443092 PMC: 11146397. DOI: 10.1136/lupus-2023-001140.

References

Prete M, Leone P, Frassanito M, Desantis V, Marasco C, Cicco S . Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus. Lupus. 2018; 27(12):1926-1935. DOI: 10.1177/0961203318797425. View

Regola F, Piantoni S, Lowin T, Archetti S, Reggia R, Kumar R . Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab. Front Pharmacol. 2019; 10:433. PMC: 6494924. DOI: 10.3389/fphar.2019.00433. View

Li H, Boulougoura A, Endo Y, Tsokos G . Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. J Autoimmun. 2022; 132:102870. DOI: 10.1016/j.jaut.2022.102870. View

Marks K, Rao D . T peripheral helper cells in autoimmune diseases. Immunol Rev. 2022; 307(1):191-202. PMC: 9009135. DOI: 10.1111/imr.13069. View

Amasaki Y, Kobayashi S, Takeda T, Ogura N, Jodo S, Nakabayashi T . Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin Exp Immunol. 1995; 99(2):245-50. PMC: 1534304. DOI: 10.1111/j.1365-2249.1995.tb05540.x. View

Goenka R, Scholz J, Sindhava V, Cancro M . New roles for the BLyS/BAFF family in antigen-experienced B cell niches. Cytokine Growth Factor Rev. 2014; 25(2):107-13. PMC: 3999179. DOI: 10.1016/j.cytogfr.2014.01.001. View

Ohl K, Tenbrock K . Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2014; 45(2):344-55. DOI: 10.1002/eji.201344280. View

Tanaka A, Maeda S, Nomura T, Llamas-Covarrubias M, Tanaka S, Jin L . Construction of a T cell receptor signaling range for spontaneous development of autoimmune disease. J Exp Med. 2022; 220(2). PMC: 9718937. DOI: 10.1084/jem.20220386. View

Lin J, Yu Y, Ma J, Ren C, Chen W . PD-1+CXCR5-CD4+T cells are correlated with the severity of systemic lupus erythematosus. Rheumatology (Oxford). 2019; 58(12):2188-2192. DOI: 10.1093/rheumatology/kez228. View

10.

Yang J, Yang X, Zou H, Chu Y, Li M . Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford). 2011; 50(8):1366-72. DOI: 10.1093/rheumatology/ker116. View

11.

Banerjee H, Nieves-Rosado H, Kulkarni A, Murter B, McGrath K, Chandran U . Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment. Cell Rep. 2021; 36(11):109699. PMC: 8482289. DOI: 10.1016/j.celrep.2021.109699. View

12.

Nakayamada S, Tanaka Y . Clinical relevance of T follicular helper cells in systemic lupus erythematosus. Expert Rev Clin Immunol. 2021; 17(10):1143-1150. DOI: 10.1080/1744666X.2021.1976146. View

13.

Parodis I, Akerstrom E, Sjowall C, Sohrabian A, Jonsen A, Gomez A . Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. Int J Mol Sci. 2020; 21(10). PMC: 7278961. DOI: 10.3390/ijms21103463. View

14.

Chen M, Lin X, Liu Y, Li Q, Deng Y, Liu Z . The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev. 2014; 25(3):301-5. PMC: 4055514. DOI: 10.1016/j.cytogfr.2013.12.011. View

15.

Ota M, Duong B, Torkamani A, Doyle C, Gavin A, Ota T . Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol. 2010; 185(7):4128-36. PMC: 3263398. DOI: 10.4049/jimmunol.1002176. View

16.

Vilas-Boas A, Morais S, Isenberg D . Belimumab in systemic lupus erythematosus. RMD Open. 2015; 1(1):e000011. PMC: 4612697. DOI: 10.1136/rmdopen-2014-000011. View

17.

Alvarez-Rodriguez L, Martinez-Taboada V, Calvo-Alen J, Beares I, Villa I, Lopez-Hoyos M . Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome. Front Immunol. 2019; 10:391. PMC: 6414457. DOI: 10.3389/fimmu.2019.00391. View

18.

Nowicka M, Krieg C, Crowell H, Weber L, Hartmann F, Guglietta S . CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Res. 2019; 6:748. PMC: 5473464. DOI: 10.12688/f1000research.11622.3. View

19.

Shin W, Lee H, Lim H, Lee S, Son J, Lee J . BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nat Commun. 2018; 9(1):1200. PMC: 5865148. DOI: 10.1038/s41467-018-03620-2. View

20.

Moore P, Belvedere O, Orr A, Pieri K, LaFleur D, Feng P . BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999; 285(5425):260-3. DOI: 10.1126/science.285.5425.260. View